Experimental hepatitis B drug may offer ‘functional cure’ for some patients

An experimental hepatitis B drug called bepirovirsen may offer a 'functional cure' for some patients, with 20% of trial participants maintaining undetectable virus levels after stopping treatment. Developed by GSK and Ionis Pharmaceuticals, the drug is under fast-track FDA review and shows potential to address chronic hepatitis B, which affects over 250 million people globally.